

PKA I β reg (h2): 293T Lysate: sc-112159

BACKGROUND

The second messenger cyclic AMP (cAMP) mediates diverse cellular responses to external signals such as proliferation, ion transport, regulation of metabolism and gene transcription by activation of the cAMP-dependent protein kinase (cAPK or PKA). Activation of PKA occurs when cAMP binds to the two regulatory subunits of the tetrameric PKA holoenzyme, resulting in release of active catalytic subunits. Four different PKA regulatory subunits have been identified, designated I α , I β , II α and II β . The PKA I α reg protein is a tissue-specific extinguisher that downregulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Functional null mutations in the gene that codes for PKA I α reg cause Carney complex (CNC). CNC is an autosomal dominant multiple neoplasia syndrome. CNC is associated with a variety of characterized symptoms such as cardiac and other myxomas, spotty skin pigmentation, endocrine tumors and psammomatous melanotic schwannomas.

REFERENCES

1. Beavo, J.A., et al. 1974. Activation of protein kinase by physiological concentrations of cyclic AMP. *Proc. Natl. Acad. Sci. USA* 71: 3580-3583.
2. Krebs, E.G. and Beavo, J.A. 1980. Phosphorylation and dephosphorylation of enzymes. *Annu. Rev. Biochem.* 48: 923-959.
3. Maldonado, F. and Hanks, S.K. 1988. cAMP-dependent protein kinase, α -catalytic subunit. *Nucleic Acids Res.* 16: 8189-8190.
4. Gonzalez, G.A. and Montminy, M.R. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. *Cell* 59: 675-680.
5. Beebe, S.J., et al. 1990. cAMP-dependent protein kinase, β -catalytic subunit. *Mol. Endocrinol.* 4: 465-475.
6. Schneider, L.H., et al. 1991. Infra-additivity of combined treatments with selective D1 and D2 receptor antagonists for inhibiting sucrose reinforcement. *Brain Res.* 550: 122-124.
7. Meinkoth, J.L., et al. 1993. Signal transduction through the cAMP-dependent protein kinase. *Mol. Cell. Biochem.* 127-128: 179-186.
8. Nordheim, A. 1994. CREB takes CBP to tango. *Nature* 370: 177-178.
9. Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 188830. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>

CHROMOSOMAL LOCATION

Genetic locus: PRKAR1B (human) mapping to 7p22.3.

PRODUCT

PKA I β reg (h2): 293T Lysate represents a lysate of human PKA I β transfected 293T cells and is provided as 100 μ g protein in 200 μ l SDS-PAGE buffer.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

APPLICATIONS

PKA I β reg (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive PKA I β reg antibodies. Recommended use: 10-20 μ l per lane.


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

PKA I α /I β reg (G-6): sc-271446 is recommended as a positive control antibody for Western Blot analysis of enhanced human PKA I β reg expression in PKA I β reg transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended:
1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

DATA



PKA I α /I β reg (G-6): sc-271446. Western blot analysis of PKA I β reg expression in non-transfected: sc-117752 (A) and human PKA I β reg transfected: sc-112159 (B) 293T whole cell lysates.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.